The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.
 
Antoine Morin Coulombe
No Relationships to Disclose
 
Guliz Ozgun
No Relationships to Disclose
 
Rebecca Johnson
No Relationships to Disclose
 
Mark Andrew Lewis
Employment - Medscape
Honoraria - Foundation Medicine
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; Exelixis; HalioDx; Ipsen; Natera; Novartis; Pfizer; QED Therapeutics
Speakers' Bureau - AstraZeneca/Daiichi Sankyo
Other Relationship - Foundation Medicine; Medscape
 
Nabil Adra
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; Exelixis; Merck; Sanofi
Research Funding - Exelixis (Inst); Genentech (Inst); Merck (Inst); Natera (Inst)
 
Scott E. Eggener
Consulting or Advisory Role - Candel Therapeutics; Francis Medical; InSightec; Profound Medical
Speakers' Bureau - Janssen
(OPTIONAL) Uncompensated Relationships - Steba Biotech
 
Bruce J. Roth
Consulting or Advisory Role - Merck; Seagen; Secura Bio
Research Funding - Medivation (Inst)
 
Christopher W. Ryan
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Daiichi Sankyo; Exelixis; Partner Therapeutics; Synox
Research Funding - Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline/Novartis (Inst); Karyopharm Therapeutics (Inst); Leducq (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Xynomic Pharma (Inst)
 
Christopher Porter
No Relationships to Disclose
 
Fred Millard
No Relationships to Disclose
 
Thomas Jang
No Relationships to Disclose
 
Robert James Hamilton
Honoraria - Astellas Pharma; Bayer; Janssen
Research Funding - Bayer; Janssen
Travel, Accommodations, Expenses - Janssen; Tolmar
 
Lawrence H. Einhorn
Stock and Other Ownership Interests - Amgen
 
Christian K. Kollmannsberger
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Merck KGaA; Pfizer
Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen; Merck; Merck KGaA; Pfizer
Travel, Accommodations, Expenses - Ipsen; Janssen Oncology; Pfizer
 
Kathryn B. Arnold
No Relationships to Disclose
 
Charles David Blanke
No Relationships to Disclose
 
Siamak Daneshmand
Stock and Other Ownership Interests - Taris
Honoraria - Aduro Biotech; Allergan (I); Bristol-Myers Squibb; Ferring; Janssen; Johnson & Johnson; Olympus; pacific edge; Photocure; QED Therapeutics
Consulting or Advisory Role - Ferring; Photocure; QED Therapeutics; Taris
Research Funding - Photocure
Travel, Accommodations, Expenses - Photocure
 
Craig R. Nichols
No Relationships to Disclose
 
Lucia Nappi
Honoraria - AstraZeneca; Bayer; Ipsen; Merck Serono; Pfizer
Consulting or Advisory Role - AstraZeneca; Bayer; Ipsen; Pfizer
Research Funding - EMD Serono (Inst); Ipsen (Inst); Janssen Oncology (Inst)
Patents, Royalties, Other Intellectual Property - IVERMECTIN ANALOGUE COMPOUND THERAPEUTICS FOR HEAT SHOCK PROTEIN-27 (HSP27) INHIBITION, METHODS AND USES ASSOCIATED THEREWITH provisional number: 62/756,707
 
Andrea Harzstark
No Relationships to Disclose